Small molecule · Modulator · developed by AIM ImmunoTech
Rintatolimod is a synthetic derivative of inosinic acid with immunomodulatory and antiviral properties. It stimulates interferon production, activates the oligoadenylate synthase-RNase L pathway and stimulates natural killer cell activity. It is studied in ovarian cancer, pancreatic cancer, HIV infection, chronic fatigue syndrome and influenza.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00215800 | Phase 3 | Chronic Fatigue Syndrome | Completed | AIM |
| NCT05927142 | Phase 1/2 | Metastatic Pancreatic Cancer | Active not recruiting | AZN |
| NCT03734692 | Phase 1/2 | Ovarian Cancer Recurrent | Active not recruiting | AIM |
| NCT01591473 | Phase 1/2 | Influenza, Human | Terminated | AIM |
| NCT00035893 | Phase 2 | HIV Seropositivity | Completed | AIM |
| NCT00215813 | N/A | Chronic Fatigue Syndrome | Temporarily not available | AIM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Pancreatic CancerOvarian Cancer RecurrentChronic Fatigue SyndromeHIV InfectionHIV SeropositivityInfluenza, HumanMyalgic Encephalomyelitis
Updated Oct 11, 2026. Something wrong or missing? Report it on the AIM page.
See AIM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AIM catalysts and pipeline →